Strides Pharma Science has received Emergency Use Authorization (EUA) from the Drugs Controller General of India (DCGI) to launch Molnupiravir 200mg in India. Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS?CoV?2 and the clinical studies have shown this drug to be active against the most common Covid?19 variants.
Under the brand name ‘Stripiravir’, Strides has developed Molnupiravir and is commercializing the product with a group integrated supply chain for Active Pharmaceutical Ingredients and solid oral dosage from its large?scale WHO Pre?Qualified (PQ) manufacturing capacities.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: